Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
-
Research Facility, Phoenix, Arizona, United States, 85054
Research Facility, Irvine, California, United States, 92618
Research Facility, Santa Monica, California, United States, 90404
Research Facility, Longmont, Colorado, United States, 80504
Research Facility, Jacksonville, Florida, United States, 32224
Research Facility, Atlanta, Georgia, United States, 30322
Research Facility, Indianapolis, Indiana, United States, 46202
Research Facility, Boston, Massachusetts, United States, 02215
Research Facility, Detroit, Michigan, United States, 48202
Research Facility, Rochester, Minnesota, United States, 55905
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
RayzeBio, Inc.,
Denis Ferreira, MD, STUDY_DIRECTOR, RayzeBio, Inc.
2033-01